» Articles » PMID: 16140347

Baclofen Reduces Fat Intake Under Binge-type Conditions

Overview
Journal Physiol Behav
Date 2005 Sep 6
PMID 16140347
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The GABA-B agonist baclofen reduces drug self-administration in rats and has shown promise clinically in the treatment of substance abuse. Baclofen generally does not reduce food intake in non-binge feeding protocols. In this study, baclofen was tested in a fat-binge protocol. Thirty male rats were divided into three groups (B: binge; FM: fat-matched; C: chow). B received a bowl of vegetable shortening for 2 h on Monday, Wednesday, and Friday (MWF) and continuous access to powdered chow (regular chow) in all phases. FM had continuous access to a regular chow+shortening mixture (FM chow) that provided the same proportion of shortening and regular chow that the B rats consumed in all phases. In addition, FM had the following: phase 1: no separate bowl of shortening; phase 2: 2-h MWF access to a separate bowl of shortening; phase 3, daily 2-h access to a separate bowl of shortening; C rats had continuous access to the regular chow in all phases. In addition, C had the following: phase 1: no separate bowl of shortening; phase 2: 2-h MWF access to a separate bowl of shortening; in phase 3, daily 2-h access to a separate bowl of shortening. Baclofen (1.0, 1.8 mg/kg, i.p.) reduced shortening intake regardless of access condition. Baclofen had no effect on, or stimulated, FM and regular chow intake. These results demonstrate that baclofen can reduce fat intake in rats under binge-type conditions. Furthermore, these results indicate that bingeing, as modeled in our protocol, is different from other forms of food intake and may share similarities with substance abuse.

Citing Articles

Systematic Review of Binge Eating Rodent Models for Developing Novel or Repurposing Existing Pharmacotherapies.

Berger G, Corris J, Fields S, Hao L, Scarpa L, Bello N Biomolecules. 2023; 13(5).

PMID: 37238615 PMC: 10216509. DOI: 10.3390/biom13050742.


GABA receptor signaling in the caudate putamen is involved in binge-like consumption during a high fat diet in mice.

Sun R, Tsunekawa T, Hirose T, Yaginuma H, Taki K, Mizoguchi A Sci Rep. 2021; 11(1):19296.

PMID: 34588513 PMC: 8481241. DOI: 10.1038/s41598-021-98590-9.


Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology.

Heal D, Smith S J Psychopharmacol. 2021; 36(6):680-703.

PMID: 34318734 PMC: 9150143. DOI: 10.1177/02698811211032475.


GABA Receptor Signaling in the Mesolimbic System Suppresses Binge-like Consumption of a High-Fat Diet.

Tsunekawa T, Banno R, Yaginuma H, Taki K, Mizoguchi A, Sugiyama M iScience. 2019; 20:337-347.

PMID: 31610370 PMC: 6817655. DOI: 10.1016/j.isci.2019.09.032.


Junk Food Exposure Disrupts Selection of Food-Seeking Actions in Rats.

Kosheleff A, Araki J, Tsan L, Chen G, Murphy N, Maidment N Front Psychiatry. 2018; 9:350.

PMID: 30166974 PMC: 6106797. DOI: 10.3389/fpsyt.2018.00350.


References
1.
Corwin R, Wojnicki F, Fisher J, Dimitriou S, Rice H, Young M . Limited access to a dietary fat option affects ingestive behavior but not body composition in male rats. Physiol Behav. 1999; 65(3):545-53. DOI: 10.1016/s0031-9384(98)00201-7. View

2.
Bonci A, Malenka R . Properties and plasticity of excitatory synapses on dopaminergic and GABAergic cells in the ventral tegmental area. J Neurosci. 1999; 19(10):3723-30. PMC: 6782740. View

3.
Xi Z, Stein E . Baclofen inhibits heroin self-administration behavior and mesolimbic dopamine release. J Pharmacol Exp Ther. 1999; 290(3):1369-74. View

4.
Flannery B, Garbutt J, Cody M, Renn W, Grace K, Osborne M . Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res. 2004; 28(10):1517-23. DOI: 10.1097/01.alc.0000141640.48924.14. View

5.
Ebenezer I, Patel S . Effects of the GABAB receptor agonists baclofen and 3-aminopropylphosphinic acid (3-APA) on food intake in rats. Methods Find Exp Clin Pharmacol. 2004; 26(8):627-30. DOI: 10.1358/mf.2004.26.8.863728. View